Changes

No change in size ,  20:23, 7 July 2018
Line 34: Line 34:     
BCR-ABL1 translocations (Ph+) are more prevalent in adult vs. pediatric patients diagnosed as Mixed Phenotype Acute Leukemia (MPAL) [12,13].  The BCR-ABL1 translocations are considered to be prognostic of poorer outcomes in the context of patients diagnosed with Mixed Phenotype Acute Leukemia (MPAL) [12].  However, a number of individual studies indicate that Ph+ MPAL patients can be treated successfully wiht tyrosine kinase inhibitors (TKI) such as Imatinab and second generation TKIs (14,15).
 
BCR-ABL1 translocations (Ph+) are more prevalent in adult vs. pediatric patients diagnosed as Mixed Phenotype Acute Leukemia (MPAL) [12,13].  The BCR-ABL1 translocations are considered to be prognostic of poorer outcomes in the context of patients diagnosed with Mixed Phenotype Acute Leukemia (MPAL) [12].  However, a number of individual studies indicate that Ph+ MPAL patients can be treated successfully wiht tyrosine kinase inhibitors (TKI) such as Imatinab and second generation TKIs (14,15).
 +
    
'''[http://www.ccga.io/index.php/Acute_Myeloid_Leukemia_(AML)_with_BCR-ABL1 Acute Myeloid Leukemia with BCR-ABL1]'''
 
'''[http://www.ccga.io/index.php/Acute_Myeloid_Leukemia_(AML)_with_BCR-ABL1 Acute Myeloid Leukemia with BCR-ABL1]'''
    
TEXT
 
TEXT
      
==Gene Overview==
 
==Gene Overview==